• Explore /
  • Poster
  • / Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).

Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).

Abstract Poster

Authors

null

Daniele Santini

Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy

Daniele Santini , Marco Stellato , Ugo De Giorgi , Sandro Pignata , Francesco Pantano , Delia De Lisi , Chiara Casadei , Marco Maruzzo , Emanuele Naglieri , Sebastiano Buti , Rocco De Vivo , Giuseppe Di Lorenzo , Andrea Sbrana , Mariella Soraru' , Giuseppe Fornarini , Claudia Mucciarini , Francesco Grillone , Giandomenico Roviello , Francesca Vignani , Giuseppe Procopio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 691)

Abstract #

691

Poster Bd #

G11

Abstract Disclosures

Similar Posters

First Author: Shaan Dudani

First Author: Daniel M. Geynisman

First Author: Neil J. Shah

First Author: Neil J. Shah